Literature DB >> 15580507

Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model.

A Maataoui1, J Qian, D Vossoughi, M F Khan, E Oppermann, W O Bechstein, T J Vogl.   

Abstract

The purpose of this study is to compare transarterial chemoembolization (TACE) alone and in combination with other therapies in an animal model. Subcapsular implantation of a solid Morris hepatoma 3924A in the liver was carried out in 50 male ACI rats (day 0). Tumor volume (V1) was measured by MRI (day 13). After laparotomy and retrograde placement of a catheter into the gastroduodenal artery (day 14), the following protocols of the interventional procedure were applied: TACE (mitomycin C + lipiodol) + immunotherapy (group A: TNFalpha + IL-2, group B: OK-432 + IL-2); TACE + antiangiogenesis therapy (group C: TNP-470, group D: endostatin); TACE alone in group E (control group). Tumor volume (V2) was assessed by MRI and the mean ratio of x (V2/V1) was calculated. Data were analyzed using Dunnett's t test (comparing therapeutic groups with the control group) and the Student-Newman-Keuls test (comparing significant therapeutic groups). Multivariate analysis showed a significant reduction in the tumor growth rate (P<0.05) in groups B (x=6.53) and C (x=4.01) compared to the mean ratio of the control group E (x=9.14). Significant results were observed in group C (P<0.05) in comparison with the other therapeutic groups. TACE combined with immunotherapy (OK-432) and antiangiogenesis therapy (TNP-470) retards tumor growth compared with TACE alone in an HCC animal model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15580507     DOI: 10.1007/s00330-004-2517-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  52 in total

1.  The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.

Authors:  W D Figg; J M Pluda; R M Lush; M W Saville; K Wyvill; E Reed; R Yarchoan
Journal:  Pharmacotherapy       Date:  1997 Jan-Feb       Impact factor: 4.705

2.  Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model.

Authors:  E A te Velde; J M Vogten; M F G B Gebbink; J M van Gorp; E E Voest; I H M Borel Rinkes
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

3.  Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy.

Authors:  Yang-Fu Jiang; Zhi-Hua Yang; Jin-Qun Hu
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

4.  Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent.

Authors:  Laure S Fournier; Charles Andre Cuenod; Cedric de Bazelaire; Nathalie Siauve; Christophe Rosty; Phuong Lan Tran; Guy Frija; Olivier Clement
Journal:  Eur Radiol       Date:  2004-07-29       Impact factor: 5.315

Review 5.  Angiogenesis: new insights and therapeutic potential.

Authors:  R J Tomanek; G C Schatteman
Journal:  Anat Rec       Date:  2000-06-15

6.  Radiofrequency thermal ablation with expandable needle of focal liver malignancies: complication report.

Authors:  Elisabetta Buscarini; Luigi Buscarini
Journal:  Eur Radiol       Date:  2003-10-17       Impact factor: 5.315

7.  IL-2 perfusion to the liver augments the hepatic extraction rate of accompanying anticancer drugs.

Authors:  K Okuno; S Kobayashi; H Jinnai; Y S Lee; H Shigeoka; M Yasutomi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 8.  Surgery and ablative therapy for hepatocellular carcinoma.

Authors:  Charles Cha; Ronald P DeMatteo; Leslie H Blumgart
Journal:  J Clin Gastroenterol       Date:  2002 Nov-Dec       Impact factor: 3.062

9.  Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography.

Authors:  Hyo-Sung Kwak; Jeong-Min Lee; Chong-Soo Kim
Journal:  Eur Radiol       Date:  2003-10-03       Impact factor: 5.315

10.  Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver.

Authors:  S Yanai; H Okada; M Misaki; K Saito; Y Kuge; Y Ogawa; H Toguchi
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

View more
  10 in total

1.  Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.

Authors:  Guang-Zhi Wang; Wei Zhang; Zhu-Ting Fang; Wen Zhang; Min-Jie Yang; Guo-Wei Yang; Shuo Li; Lian Zhu; Li-Li Wang; Wei-Sheng Zhang; Rong Liu; Sheng Qian; Jian-Hua Wang; Xu-Dong Qu
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-23       Impact factor: 4.553

2.  Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT).

Authors:  Stephan Zangos; Katrin Eichler; Jörn O Balzer; Ralf Straub; Renate Hammerstingl; Christopher Herzog; Thomas Lehnert; Mathias Heller; Axel Thalhammer; Martin G Mack; Thomas J Vogl
Journal:  Eur Radiol       Date:  2006-08-08       Impact factor: 5.315

3.  Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma and coexisting hepatic cavernous hemangioma.

Authors:  Ran-Chou Chen; Jiunn-Ming Lii; Wei-Tsung Chen; Hsing-Yang Tu; Liang-Chung Chiang
Journal:  Eur Radiol       Date:  2005-12-06       Impact factor: 5.315

Review 4.  Interventional therapies of unresectable liver metastases.

Authors:  Jun Qian
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-11       Impact factor: 4.553

5.  Disposition of ultrasound sensitive polymeric drug carrier in a rat hepatocellular carcinoma model.

Authors:  Michael C Cochran; John R Eisenbrey; Michael C Soulen; Susan M Schultz; Richard O Ouma; Sarah B White; Emma E Furth; Margaret A Wheatley
Journal:  Acad Radiol       Date:  2011-11       Impact factor: 3.173

Review 6.  Hepatocellular carcinoma: insight from animal models.

Authors:  Yan Li; Zhao-You Tang; Jin-Xuan Hou
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-25       Impact factor: 46.802

7.  Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).

Authors:  Andrea Veltri; Paolo Moretto; Andrea Doriguzzi; Eva Pagano; Giovanna Carrara; Giovanni Gandini
Journal:  Eur Radiol       Date:  2005-10-14       Impact factor: 5.315

8.  Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model.

Authors:  Sanjay Gupta; Kenneth C Wright; Joe Ensor; Carolyn S Van Pelt; Katherine A Dixon; Vikas Kundra
Journal:  Cardiovasc Intervent Radiol       Date:  2011-04-09       Impact factor: 2.740

9.  Development of a High-Throughput Molecular Imaging-Based Orthotopic Hepatocellular Carcinoma Model.

Authors:  Gloria L Hwang; Maurice A van den Bosch; Young I Kim; Regina Katzenberg; Juergen K Willmann; Ramasamy Paulmurugan; Sanjiv S Gambhir; Lawrence Hofmann
Journal:  Cureus       Date:  2015-06-27

10.  A comparative study on the hepatoprotective action of bear bile and Coptidis Rhizoma aqueous extract on experimental liver fibrosis in rats.

Authors:  Ning Wang; Yibin Feng; Fan Cheung; Oi-Yee Chow; Xuanbin Wang; Weiwei Su; Yao Tong
Journal:  BMC Complement Altern Med       Date:  2012-11-29       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.